A
research study titled, “Biosimulation Market by Product, Application, and End
User - Global Industry Analysis and Forecast to 2025” published by Crystal
Market Research, states that the biosimulation market is projected to be around
$4 billion by 2025.
A
typical drug discovery and development cycle, which encompasses the time taken
for discovery of a new drug and its delivery to the market, may easily take up
to 10 to 15 years. The process of drug discovery which starts with discovering
a new drug molecule to registering the drug for marketing and commercialization
is a very lengthy and complex process. A heavy capital investment, a
considerable amount of time and series of clinical trials are required before a
drug is registered for human use. FDA launched the Critical Path Initiative
(CPI), in 2004, to promote innovation in scientific processes by which medical
products are developed, examined and manufactured.
Biosimulation
is one such promising notion to drug discovery and development. It has been
developed in order to avoid the hurdles in discovery and development of a new
drug by traditional processes. It promises tremendous benefits saving both
money and time and improves the predictability in early stage of the drug
development. In biosimulation, the relationships between different biological
elements are represented using differential equations utilizing simulation
techniques to predict the behavior of the biological system and status of
biological elements over time.
Rise
in cases of chronic diseases such as diabetes, high drug resistance exhibited
by certain disease related pathogens, and rapidly aging population worldwide
are some of the factors encouraging biosimulation market. Moreover, high drug
failure rate and availability of advanced modeling and simulation tools will
further contribute to the market growth.
Browse
full research report with TOC @: https://www.crystalmarketresearch.com/report/biosimulation-market
In
2016, the software segment accounted for over half of the global market,due to
the high accuracy of computer modeling in biosimulation to improve drug
molecules. In terms of applications, the drug discovery marketis expected to
show an impressive growth rate over the forecast period due to the benefits of
biosimulation processesin assisting the researchers in identifying critical
gaps that hamper the drug discovery process.
Pharmaceutical
and biotechnology companiessegment held more than half of the global market in
2016. This large share can be attributed to the rising acceptance of in silico
models (biological experiments performed entirely by means of a computer) for
drug discovery and development. Large numbers of pharmaceutical and
biotechnology companies are aggressively using computer models to create more
advanced and effective drug variants. For example, in January 2017, Certara,
the global biosimulation drug development company, announced the release of
version 16 of its Simcyp Population-based Simulator, which is one of the most
sophisticated platforms to determine first in-human dose selection.
U.S.
accounted for the major share of the North American market in 2016, due to the
high prevalence of chronic diseases, rapidly growing elderly population, which
is more prone to these diseases and are in need of treatment options such as
drugs, and strategic collaborations among leading players. For instance,
Certara in September 2016 acquired Australia based d3 Medicine to strengthen
their ability to deliver optimized drug development plans to their
clients.Also, there is rise in research activities on biosimulation in the
region which will facilitate the market growth. For instance, in April 2016,
Certara launched an e-learning platform under Certara University to facilitate
education in the field of biosimulation and model based drug development.
Emerging economies in Asia-Pacific biosimulation market will exhibit the
fastest growth in the forecast period due to emphasis on research and
development initiatives and rising focus of international playerson the
emerging markets. For instance, in January 2016, Certara launched a strategic
drug development consulting company in China, named, Certara Strategic
Consulting.
The
competitive market for biosimulation is driven by strategic collaborations and
acquisitions by leading players to strengthen their research and development
capabilities and to expand their existing product portfolio. For instance, in
late December 2015, Certaraacquired XenologiQ, a UK based quantitative systems
pharmacology (QSP) firm, to strengthen its modeling and simulation
capabilities. Some of the leading players in biosimulation market are, Certara
USA, Inc., Dassault Systèmes SA, Accelrys, Compugen, Rhenovia Pharma, Lead
Scope Inc., Simulations Plus, Inc. and Evidera, Inc.
To
request a sample copy or view summary of this report, click the link below:
Key
Findings of the Research Study:
- The
biosimulation market will be majorly driven by rise in chronic disease
incidence such as cancer and diabetes, increasing prevalence of geriatric
population, high drug resistance by certain disease related pathogens and
high drug failure rate.
- The
services segment will exhibit favorable growth over the forecast period as
more and more pharmaceutical companies are beginning to outsource their
biosimulation processes in order to reduce costs and focus on core
competencies.
- North
America held a major share of the biosimulation market in 2016, commanding
over more than half of the market. Due to presence of highly skilled
professionals and research infrastructure along with presence of
regulatory authorities ensuring patient safety, this market will show
promising growth over the forecast period.
- Asia-Pacific
market will exhibit the fastest growth rate during the forecast period due
to rapidly improving healthcare infrastructure and growing Healthcare IT
expenditure.
Buy now this report @: http://www.crystalmarketresearch.com/checkout/HC0637
No comments:
Post a Comment